Biopharmaceutical raw materials provider Biosynth has officially opened the expanded GMP bioconjugation facility at its Berlin, Germany site.
The site includes specialist manufacturing infrastructure designed to produce conjugate vaccines and drugs, as well as activated PEGs and polymer-based drug delivery excipients.
Through this manufacturing capacity expansion, Biosynth will be better equipped to produce specialist ingredients for the biopharma, life science and diagnostic fields.
Biosynth's expanded bioconjugation facility also houses class C and D cleanrooms, ensuring the company is GMP-compliant and equipped to serve its growing customer base in Europe and further afield.
This strategic expansion complements the company's global growth, which was previously marked by the opening of a Biotech site in Suzhou, China.
Biosynth's investment into its bioconjugation capacity comes at a time when many bioconjugate therapeutics are in development, meaning biopharmaceutical companies are increasingly looking to outsource their associated raw materials.
"By opening the new expansion to our bioconjugation facility in Berlin, we have significantly enahnced our existing operations," noted Thomas Eisele, Chief Operations Officer of Biosynth.
"This suite will enable us to provide scalable, diverse and high-quality conjugation services to our customers, who are creating the next generation of therapies for patients across the globe."
"Conjugation chemistry, advanced polymers and bioconjugation production are critical areas for many of our life science customers,” added Marie Leblanc, Executive VP, Life Sciences.
“Being able to support projects fully, from initial bioconjugate process development to commercial GMP supply, enables us to provide specialised conjugation solutions for diagnostics and therapeutics—strengthening our position as a trusted partner in the Life Science industry,” she concluded.
